Navigation Links
US investment in biomedical and health research on downward trend
Date:10/25/2012

WASHINGTON, DCOctober 25, 2012Biomedical and health research and development (R&D) spending from all sources declined by more than $4 billion or 3% between FY10 and FY11 according to Research!America's 2011 U.S. Investment in Health Research report. This represents the first drop in overall spending since Research!America began compiling the data in 2002.

The decline follows an uptick in research funding attributed to the American Recovery and Reinvestment Act (ARRA), which allocated $10.4 billion to the National Institutes of Health (NIH) over two fiscal years (2009-2010). The overall downward trend in R&D spending is coming at a time when other nations are ramping up their own investments in research, and meanwhile, pending across-the-board budget cuts (sequestration) could reduce federal biomedical and health research funding by 8%-10% or more.

"Insufficient funding, coupled with deep budget cuts under sequestration, could be devastating for research," said Research!America's chair, former Congressman John E. Porter. "Our global competitiveness hinges on a robust investment that will support bright scientific minds, create high-quality jobs and provide a catalyst for private sector innovation."

Research!America's 2011 U.S. Investment in Health Research report shows varying levels of health research funding in the private and public sector. For example, federal funding for research totaled $39.5 billion in FY11, a 14% decrease from the previous year's total of $45.9 billion. Agency funds were distributed across all 50 states to hospitals, universities, independent research institutes and small businesses. Under sequestration, the NIH would lose $2.53 billion in funding in FY13.

"As R&D spending abroad outpaces federal investments here at home, U.S. companies will set up shop in countries with stronger policies to support research," said Mary Woolley, president and CEO of Research!America. "We cannot afford to become complacent as cures for Alzheimer's, cancer, heart disease and other serious health threats remain a priority for every American."

Overall, private industry has continually increased investments in R&D a total of $77.6 billion in 2011, a 1.4% increase from 2010, despite inflationary pressure and the economic recession. The pharmaceutical industry increased its investment to $38.5 billion, a 3% increase from the previous year. In contrast, biotechnology investment declined by nearly $800 million, or 3%. The medical device and technology sector slightly increased investment in research, totaling $9.8 billion. Currently, more than 80% of R&D among PhRMA member companies is conducted in the United States, but R&D spending abroad has more than doubled over the past decade.

Aside from federal and industry investment, other institutions spent $19.1 billion on health research, an increase of about 5% from the previous year. Universities increased spending of institutional funds for research to $11.9 billion in 2010, a 6% increase. Philanthropic spending decreased slightly, while voluntary health groups increased investment in research by 15%, or $131 million, from the prior year.

According to funding projections in the report, the research investment landscape could worsen in 2013 and over the next decade. The scenario is different in other countries; as just one example, China has identified biotechnology as one of the seven "strategic and emerging (SEI) pillar" industries and has pledged to invest $308.5 billion in biotechnology over the next 5 years. Overall, the report provides analysis that outlines health research as one of the underpinnings of the U.S. economy and a key to improving the health of Americans.


'/>"/>
Contact: Anna Briseno
abriseno@researchamerica.org
571-482-2737
Research!America
Source:Eurekalert

Related biology news :

1. Amarantus BioSciences to Present at the National Investment Banking Associations (NIBA)122nd Conference in New York City
2. AZTI-Tecnalia leads 2 research projects on bluefin tuna with 1.5 million euros investment
3. Nuisance seaweed found to produce compounds with biomedical potential
4. MADRID-MIT M+Vision Consortium hosts Biomedical Innovation Conference 2012
5. UMass Medical School scientist named 2012 Pew Latin-American Fellow in the Biomedical Sciences
6. 22 of Americas most promising scientists selected as Pew Biomedical Scholars
7. Top young Latin-American scientists named Pew Biomedical Fellows
8. Saladax Biomedical Enters into Master Collaboration Agreement with Bristol-Myers Squibb
9. BGI Tech and BAB jointly develop transgenic mice platform for biomedical research
10. Reproducibility Initiative to increase the value of biomedical research
11. £30 million boost for biomedical engineering research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/30/2017)... 2017 Trends, opportunities and forecast in this ... technology (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, ... end use industry (government and law enforcement, commercial and ... and others), and by region ( North America ... Asia Pacific , and the Rest of the ...
(Date:3/27/2017)... CENTRE, N.Y. , March 27, 2017 /PRNewswire-USNewswire/ ... Healthcare Information and Management Systems Society (HIMSS) Analytics ... Outpatient EMR Adoption Model sm . In addition, ... 12% of U.S. hospitals using an electronic medical ... CHS for its high level of EMR usage ...
Breaking Biology News(10 mins):
(Date:6/27/2017)... ... June 27, 2017 , ... DuPont Pioneer (DuPont) and ERS ... the ERS patent portfolio covering CRISPR-Cas genome editing technology for all agricultural uses ... (IP) of the CRISPR-Cas technology from co-inventor and co-owner Emmanuelle Charpentier, Ph.D. ...
(Date:6/23/2017)... ... June 23, 2017 , ... Biova, LLC., the leader in water ... Board of Directors. Dr. Henig will bring a wealth of scientific experience in the ... the Chief Technical and Scientific Officer of four major global companies in the last ...
(Date:6/22/2017)... ... 21, 2017 , ... Beaker, the industry’s pioneer in developing ... sciences industry, today announces a strategic partnership with Alcami Corporation, a leading global ... Beaker’s expertise in executive recruitment solutions, providing Alcami with access to the best ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... RegMedNet has produced a Spotlight series on “Cell Therapy Regulation” ... perspectives by leading experts on the unique regulatory challenges of stem cell medical ...
Breaking Biology Technology: